Alzamend Neuro (ALZN) Competitors

$1.03 +0.02 (+1.47%)

As of 02:41 PM Eastern

ALZN vs. APLT, CVKD, LIAN, MAAQ, and ZIVO

Should you buy Alzamend Neuro stock or one of its competitors? MarketBeat compares Alzamend Neuro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alzamend Neuro include Applied Therapeutics (APLT), Cadrenal Therapeutics (CVKD), LianBio (LIAN), Mana Capital Acquisition (MAAQ), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry.

How does Alzamend Neuro compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

In the previous week, Alzamend Neuro had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Alzamend Neuro and 0 mentions for Applied Therapeutics. Alzamend Neuro's average media sentiment score of 1.89 beat Applied Therapeutics' score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Alzamend Neuro	Very Positive

Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.11, suggesting that its share price is 89% less volatile than the broader market.

Alzamend Neuro has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Applied Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 2,605.31%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Applied Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alzamend Neuro's return on equity of -177.52% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Alzamend Neuro	N/A	-177.52%	-140.41%

Summary

Alzamend Neuro beats Applied Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Alzamend Neuro compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Cadrenal Therapeutics presently has a consensus target price of $13.00, suggesting a potential upside of 162.63%. Alzamend Neuro has a consensus target price of $28.00, suggesting a potential upside of 2,605.31%. Given Alzamend Neuro's higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cadrenal Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.89 beat Cadrenal Therapeutics' score of 1.43 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
Alzamend Neuro	Very Positive

Alzamend Neuro's return on equity of -177.52% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Alzamend Neuro	N/A	-177.52%	-140.41%

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Alzamend Neuro beats Cadrenal Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Alzamend Neuro compare to LianBio?

LianBio (NASDAQ:LIAN) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 2,605.31%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

74.8% of LianBio shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alzamend Neuro is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

In the previous week, Alzamend Neuro had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for Alzamend Neuro and 0 mentions for LianBio. Alzamend Neuro's average media sentiment score of 1.89 beat LianBio's score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Alzamend Neuro	Very Positive

LianBio's return on equity of -33.17% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Alzamend Neuro	N/A	-177.52%	-140.41%

Summary

LianBio beats Alzamend Neuro on 7 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Mana Capital Acquisition?

Mana Capital Acquisition (NASDAQ:MAAQ) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Mana Capital Acquisition's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mana Capital Acquisition	N/A	N/A	N/A
Alzamend Neuro	N/A	-177.52%	-140.41%

Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 2,605.31%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Mana Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Alzamend Neuro had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Alzamend Neuro and 0 mentions for Mana Capital Acquisition. Alzamend Neuro's average media sentiment score of 1.89 beat Mana Capital Acquisition's score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Mana Capital Acquisition	Neutral
Alzamend Neuro	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

Summary

Alzamend Neuro beats Mana Capital Acquisition on 6 of the 9 factors compared between the two stocks.

How does Alzamend Neuro compare to ZIVO Bioscience?

Alzamend Neuro (NASDAQ:ALZN) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Alzamend Neuro has a beta of 0.11, indicating that its share price is 89% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ZIVO Bioscience's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Alzamend Neuro has higher earnings, but lower revenue than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
ZIVO Bioscience	$15.85K	1,063.54	-$7.78M	-$2.59	N/A

Alzamend Neuro currently has a consensus price target of $28.00, suggesting a potential upside of 2,605.31%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, research analysts clearly believe Alzamend Neuro is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Alzamend Neuro and Alzamend Neuro both had 1 articles in the media. Alzamend Neuro's average media sentiment score of 1.89 beat ZIVO Bioscience's score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
Alzamend Neuro	Very Positive
ZIVO Bioscience	Neutral

Summary

Alzamend Neuro beats ZIVO Bioscience on 10 of the 13 factors compared between the two stocks.

Get Alzamend Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALZN vs. The Competition

Export

Metric	Alzamend Neuro	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.94M	$3.27B	$6.24B	$12.21B
Dividend Yield	N/A	2.34%	2.81%	5.30%
P/E Ratio	-0.48	18.45	20.67	25.15
Price / Sales	N/A	280.36	547.14	70.90
Price / Cash	N/A	55.27	27.48	37.27
Price / Book	0.21	6.58	9.70	6.65
Net Income	-$4.51M	$24.40M	$3.56B	$335.32M
7 Day Performance	-1.43%	-3.03%	-1.79%	-1.71%
1 Month Performance	-7.59%	-3.27%	-2.50%	-1.07%
1 Year Performance	-69.56%	57.30%	31.39%	28.18%

Alzamend Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALZN Alzamend Neuro	3.7256 of 5 stars	$1.04 +1.5%	$28.00 +2,605.3%	-70.0%	$3.94M	N/A	N/A	4	Positive News Gap Up
APLT Applied Therapeutics	1.4065 of 5 stars	$0.10 flat	$1.25 +1,113.6%	N/A	$15.86M	$1M	N/A	30
CVKD Cadrenal Therapeutics	2.92 of 5 stars	$5.19 -6.0%	$13.00 +150.5%	-67.4%	$15.84M	N/A	N/A	4
LIAN LianBio	N/A	$0.14 flat	N/A	-76.3%	$15.13M	N/A	N/A	110
MAAQ Mana Capital Acquisition	N/A	$1.85 +1.1%	N/A	-59.6%	$15.03M	N/A	N/A	1

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALZN) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alzamend Neuro (ALZN) Competitors

ALZN vs. APLT, CVKD, LIAN, MAAQ, and ZIVO

How does Alzamend Neuro compare to Applied Therapeutics?

Summary

How does Alzamend Neuro compare to Cadrenal Therapeutics?

Summary

How does Alzamend Neuro compare to LianBio?

Summary

How does Alzamend Neuro compare to Mana Capital Acquisition?

Summary

How does Alzamend Neuro compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alzamend Neuro (ALZN) Competitors

ALZN vs. APLT, CVKD, LIAN, MAAQ, and ZIVO

How does Alzamend Neuro compare to Applied Therapeutics?

Does the media refer more to APLT or ALZN?

Which has more volatility and risk, APLT or ALZN?

Which has higher earnings & valuation, APLT or ALZN?

Do insiders and institutionals believe in APLT or ALZN?

Do analysts prefer APLT or ALZN?

Is APLT or ALZN more profitable?

Summary

How does Alzamend Neuro compare to Cadrenal Therapeutics?

Do analysts prefer CVKD or ALZN?

Which has more risk and volatility, CVKD or ALZN?

Does the media prefer CVKD or ALZN?

Is CVKD or ALZN more profitable?

Which has preferable earnings & valuation, CVKD or ALZN?

Do insiders & institutionals have more ownership in CVKD or ALZN?

Summary

How does Alzamend Neuro compare to LianBio?

Do analysts recommend LIAN or ALZN?

Do institutionals & insiders believe in LIAN or ALZN?

Which has better valuation & earnings, LIAN or ALZN?

Which has more risk and volatility, LIAN or ALZN?

Does the media favor LIAN or ALZN?

Is LIAN or ALZN more profitable?

Summary

How does Alzamend Neuro compare to Mana Capital Acquisition?

Is MAAQ or ALZN more profitable?

Do analysts prefer MAAQ or ALZN?

Do insiders & institutionals believe in MAAQ or ALZN?

Does the media favor MAAQ or ALZN?

Which has better valuation & earnings, MAAQ or ALZN?

Summary

How does Alzamend Neuro compare to ZIVO Bioscience?

Which has more volatility and risk, ALZN or ZIVO?

Do institutionals and insiders hold more shares of ALZN or ZIVO?

Is ALZN or ZIVO more profitable?

Which has better earnings and valuation, ALZN or ZIVO?

Do analysts prefer ALZN or ZIVO?

Does the media prefer ALZN or ZIVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools